Marco Herling, MD, University of Leipzig, Leipzig, Germany, comments on the management of transplant-ineligible patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), explaining that patients should be treated with tagraxofusp due to its tolerable toxicity profile. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
